Brian Mueller - 28 Feb 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Financial Officer
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
28 Feb 2023
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 15:10:40 UTC
Previous filing
17 Jan 2023
Next filing
17 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $0 +12,660 +46% $0.000000 40,406 28 Feb 2023 Direct F1, F2, F3
transaction BMRN Common Stock Award $0 +10,980 +27% $0.000000 51,386 28 Feb 2023 Direct F1, F3, F4
transaction BMRN Common Stock Award $0 +1,250 +2.4% $0.000000 52,636 28 Feb 2023 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
F2 Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F3 Although earned, the RSUs only vest according to the following schedule: approximately 20% vests on March 16, 2023 and approximately 80% vests on June 29, 2023, subject to the reporting person's continued service through such dates, subject to earlier vesting upon certain events.
F4 Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F5 Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.